Literature DB >> 25313000

Pharmacologic rescue of motor and sensory function by the neuroprotective compound P7C3 following neonatal nerve injury.

S W P Kemp1, M Szynkaruk2, K N Stanoulis2, M D Wood3, E H Liu2, M P Willand3, L Morlock4, J Naidoo4, N S Williams4, J M Ready4, T J Mangano5, S Beggs6, M W Salter6, T Gordon3, A A Pieper7, G H Borschel8.   

Abstract

Nerve injuries cause pain, paralysis and numbness that can lead to major disability, and newborns often sustain nerve injuries during delivery that result in lifelong impairment. Without a pharmacologic agent to enhance functional recovery from these injuries, clinicians rely solely on surgery and rehabilitation to treat patients. Unfortunately, patient outcomes remain poor despite application of the most advanced microsurgical and rehabilitative techniques. We hypothesized that the detrimental effects of traumatic neonatal nerve injury could be mitigated with pharmacologic neuroprotection, and tested whether the novel neuroprotective agent P7C3 would block peripheral neuron cell death and enhance functional recovery in a rat neonatal nerve injury model. Administration of P7C3 after sciatic nerve crush injury doubled motor and sensory neuron survival, and also promoted axon regeneration in a dose-dependent manner. Treatment with P7C3 also enhanced behavioral and muscle functional recovery, and reversed pathological mobilization of spinal microglia after injury. Our findings suggest that the P7C3 family of neuroprotective compounds may provide a basis for the development of a new neuroprotective drug to enhance recovery following peripheral nerve injury.
Copyright © 2014 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  P7C3; functional recovery; microglia; neonatal nerve injury; neuroprotection

Mesh:

Substances:

Year:  2014        PMID: 25313000     DOI: 10.1016/j.neuroscience.2014.10.005

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  17 in total

Review 1.  Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury.

Authors:  Meghan O Blaya; Joseph M Wasserman; Andrew A Pieper; Thomas J Sick; Helen M Bramlett; W Dalton Dietrich
Journal:  Neuropharmacology       Date:  2018-09-17       Impact factor: 5.250

2.  Beneficial Effects of Delayed P7C3-A20 Treatment After Transient MCAO in Rats.

Authors:  Zachary B Loris; Justin R Hynton; Andrew A Pieper; W Dalton Dietrich
Journal:  Transl Stroke Res       Date:  2017-08-25       Impact factor: 6.829

3.  Neuroprotective effects of P7C3 against spinal cord injury in rats.

Authors:  Fei-Xiang Duan; Yu-Jiao Shi; Jing Chen; Shu-Qin Ding; Feng-Chao Wang; Jie Tang; Rui Wang; Lin Shen; Jin Xi; Qi Qi; He-Zuo Lü; Jian-Guo Hu
Journal:  Exp Biol Med (Maywood)       Date:  2019-11-13

Review 4.  From Gene to Behavior: L-Type Calcium Channel Mechanisms Underlying Neuropsychiatric Symptoms.

Authors:  Zeeba D Kabir; Arlene Martínez-Rivera; Anjali M Rajadhyaksha
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

5.  Cacna1c: Protecting young hippocampal neurons in the adult brain.

Authors:  Héctor De Jesús-Cortés; Anjali M Rajadhyaksha; Andrew A Pieper
Journal:  Neurogenesis (Austin)       Date:  2016-09-02

6.  Early detection of subclinical visual damage after blast-mediated TBI enables prevention of chronic visual deficit by treatment with P7C3-S243.

Authors:  Laura M Dutca; Steven F Stasheff; Adam Hedberg-Buenz; Danielle S Rudd; Nikhil Batra; Frederick R Blodi; Matthew S Yorek; Terry Yin; Malini Shankar; Judith A Herlein; Jacinth Naidoo; Lorraine Morlock; Noelle Williams; Randy H Kardon; Michael G Anderson; Andrew A Pieper; Matthew M Harper
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-02       Impact factor: 4.799

7.  Cardioprotective Effects of 1-(3,6-Dibromo-carbazol-9-yl)-3-Phenylamino-Propan-2-Ol in Diabetic Hearts via Nicotinamide Phosphoribosyltransferase Activation.

Authors:  Jared Tur; Sachin L Badole; Ravikumar Manickam; Kalyan C Chapalamadugu; Wanling Xuan; Wayne Guida; Jaret J Crews; Kirpal S Bisht; Srinivas M Tipparaju
Journal:  J Pharmacol Exp Ther       Date:  2022-06-09       Impact factor: 4.402

8.  (-)-P7C3-S243 Protects a Rat Model of Alzheimer's Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia.

Authors:  Jaymie R Voorhees; Matthew T Remy; Coral J Cintrón-Pérez; Eli El Rassi; Michael Z Khan; Laura M Dutca; Terry C Yin; Latisha N McDaniel; Noelle S Williams; Daniel J Brat; Andrew A Pieper
Journal:  Biol Psychiatry       Date:  2017-11-06       Impact factor: 13.382

9.  Maternal P7C3-A20 Treatment Protects Offspring from Neuropsychiatric Sequelae of Prenatal Stress.

Authors:  Rachel Schroeder; Preethy Sridharan; Lynn Nguyen; Alexandra Loren; Noelle S Williams; Kavitha P Kettimuthu; Coral J Cintrón-Pérez; Edwin Vázquez-Rosa; Andrew A Pieper; Hanna E Stevens
Journal:  Antioxid Redox Signal       Date:  2021-01-29       Impact factor: 7.468

10.  Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease.

Authors:  Héctor De Jesús-Cortés; Adam D Miller; Jeremiah K Britt; Anthony J DeMarco; Mayralis De Jesús-Cortés; Emily Stuebing; Jacinth Naidoo; Edwin Vázquez-Rosa; Lorraine Morlock; Noelle S Williams; Joseph M Ready; Nandakumar S Narayanan; Andrew A Pieper
Journal:  NPJ Parkinsons Dis       Date:  2015-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.